Caption: Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the company's PLacental eXpanded (PLX) cells demonstrated efficacy in a preliminary animal experiment for the treatment of Graf
Credit: Pluristem Therapeutics